

## Moxifloxacin Liquid Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.2                09/13/2019              1731714-00006        Date of first issue: 06/05/2017

---

### SECTION 1. IDENTIFICATION

Product name                                : Moxifloxacin Liquid Formulation

#### Manufacturer or supplier's details

Company name of supplier                : Merck & Co., Inc  
Address                                        : 2000 Galloping Hill Road  
    Kenilworth - New Jersey - U.S.A. 07033  
Telephone                                    : 908-740-4000  
Telefax                                        : 908-735-1496  
Emergency telephone                       : 1-908-423-6000  
E-mail address                               : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use                            : Pharmaceutical

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with 29 CFR 1910.1200

Reproductive toxicity                        : Category 2

#### GHS label elements

Hazard pictograms                            :



Signal Word                                    : Warning

Hazard Statements                            : H361d Suspected of damaging the unborn child.

Precautionary Statements                 :  
**Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
**Storage:**  
P405 Store locked up.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

#### Other hazards

None known.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

## Moxifloxacin Liquid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731714-00006      Date of last issue: 04/24/2019  
 Date of first issue: 06/05/2017

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 0.1 - <= 0.2

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : No hazardous combustion products are known
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.
- Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

## Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

for fire-fighters

Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid inhalation of vapor or mist.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

## Moxifloxacin Liquid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731714-00006      Date of last issue: 04/24/2019  
 Date of first issue: 06/05/2017

		(Form of exposure)	ters / Permissible concentration	
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m <sup>3</sup> (OEB 2)	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Laboratory operations do not require special containment.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**  
**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : liquid  
**Color** : yellow  
**Odor** : odorless

**Moxifloxacin Liquid Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.2                09/13/2019              1731714-00006        Date of first issue: 06/05/2017

---

Odor Threshold                            : No data available

pH    : 4.1 - 4.6

Melting point/freezing point           : No data available

Initial boiling point and boiling range : No data available

Flash point                                : No data available

Evaporation rate                         : No data available

Flammability (solid, gas)               : Not applicable

Flammability (liquids)                 : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure                            : No data available

Relative vapor density                  : No data available

Relative density                         : No data available

Density                                    : 1.0044 g/cm<sup>3</sup> (68 °F / 20 °C)

Solubility(ies)  
  Water solubility                        : slightly soluble

Partition coefficient: n-octanol/water : No data available

Autoignition temperature               : No data available

Decomposition temperature             : No data available

Viscosity  
  Viscosity, kinematic                  : No data available

Explosive properties                    : Not explosive

Oxidizing properties                    : The substance or mixture is not classified as oxidizing.

Molecular weight                        : No data available

Particle size                              : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

## Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

---

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Acute oral toxicity	:	LD50 (Rat): 1,320 mg/kg
		LD50 (Mouse): > 435 mg/kg
		LD50 (Monkey): 1,500 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	:	Rabbit
Result	:	No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	:	Rabbit
Result	:	Moderate eye irritation

#### Respiratory or skin sensitization

##### Skin sensitization

Not classified based on available information.

##### Respiratory sensitization

Not classified based on available information.

## Moxifloxacin Liquid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731714-00006      Date of last issue: 04/24/2019  
Date of first issue: 06/05/2017

---

### **Germ cell mutagenicity**

Not classified based on available information.

### **Components:**

#### **Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: in vitro micronucleus test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Application Route: Oral  
Result: negative

### **Carcinogenicity**

Not classified based on available information.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### **Reproductive toxicity**

Suspected of damaging the unborn child.

### **Components:**

#### **Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: LOAEL: 500 mg/kg body weight  
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Monkey  
Application Route: Oral  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: negative

Test Type: Embryo-fetal development  
Species: Rabbit

## Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

---

Application Route: Intravenous injection  
 Developmental Toxicity: LOAEL: 20 mg/kg body weight  
 Symptoms: Skeletal malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Not classified based on available information.

### Components:

#### Moxifloxacin HCL:

Target Organs : Liver  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### Moxifloxacin HCL:

Species : Rat  
 LOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Weeks

Species : Rat  
 NOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Liver  
 Symptoms : Liver disorders

Species : Rat  
 NOAEL : 20 mg/kg  
 Application Route : Oral  
 Exposure time : 6 Months  
 Target Organs : Liver  
 Symptoms : Liver disorders

Species : Monkey  
 NOAEL : 50 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Weeks  
 Symptoms : No adverse effects.

Species : Monkey  
 NOAEL : 15 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Gastrointestinal tract



**Moxifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

---

Symptoms : Vomiting

Species : Monkey

Application Route : Oral

Exposure time : 26 Weeks

Target Organs : Liver

Symptoms : Liver disorders

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Moxifloxacin HCL:**

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity**

No data available

**Persistence and degradability**

No data available

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

**Moxifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

---

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

---

**SECTION 15. REGULATORY INFORMATION****EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Reproductive toxicity

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations****Pennsylvania Right To Know**

Water

7732-18-5

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined


## Moxifloxacin Liquid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731714-00006      Date of last issue: 04/24/2019  
 Date of first issue: 06/05/2017

### SECTION 16. OTHER INFORMATION

#### Further information

##### NFPA 704:



##### HMIS® IV:

<b>HEALTH</b>	*	<b>0</b>
<b>FLAMMABILITY</b>		<b>1</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -

## Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731714-00006	Date of first issue: 06/05/2017

---

United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8